Drug intelligence / Profile preview

NP-18-3

Development stage: Unknown
Lead developer: Nanopharmaceutics
Modality: Small Molecules

Overview

**NP-18-3** is a small molecule drug candidate developed by Nanopharmaceutics, Inc., targeting central nervous system (CNS) disorders. It is part of the company's clinical pipeline, which leverages nanoparticle and fine-particle formulations to enhance drug absorption and stability for challenging BCS category II and IV compounds. Specific details on its mechanism of action, indications, or development phase are not publicly detailed beyond its CNS focus, distinguishing it from related compounds like NP-18-2, a 5-HT2B receptor antagonist also in the pipeline.[5][7]

Beyond the preview

Go deeper on NP-18-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP-18-3.

Explore the full profile